Search Results - "TENNEY, Daniel J"

Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy by Tenney, Daniel J., Rose, Ronald E., Baldick, Carl J., Pokornowski, Kevin A., Eggers, Betsy J., Fang, Jie, Wichroski, Michael J., Xu, Dong, Yang, Joanna, Wilber, Richard B., Colonno, Richard J.

“…Patients with chronic hepatitis B virus (HBV) infection who develop antiviral resistance lose benefits of therapy and may be predisposed to further resistance…”
Get full text

Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection by Balsitis, Scott, Gali, Volodymyr, Mason, Pamela J, Chaniewski, Susan, Levine, Steven M, Wichroski, Michael J, Feulner, Michael, Song, Yunling, Granaldi, Karen, Loy, James K, Thompson, Chris M, Lesniak, Jacob A, Brockus, Catherine, Kishnani, Narendra, Menne, Stephan, Cockett, Mark I, Iyer, Renuka, Mason, Stephen W, Tenney, Daniel J

“…Immune clearance of Hepatitis B virus (HBV) is characterized by broad and robust antiviral T cell responses, while virus-specific T cells in chronic hepatitis…”
Get full text

Entecavir therapy for lamivudine‐refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks by Sherman, Morris, Yurdaydin, Cihan, Simsek, Halis, Silva, Marcelo, Liaw, Yun‐Fan, Rustgi, Vinod K., Sette, Hoel, Tsai, Naoky, Tenney, Daniel J., Vaughan, James, Kreter, Bruce, Hindes, Robert

“…In hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B patients who were refractory to current lamivudine therapy, switching to entecavir was superior…”
Get full text

Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present by TENNEY, Daniel J, ROSE, Ronald E, EGGERS, Betsy, HSU, Mayla, MARY JANE PLYM, POUNDSTONE, Patricia, YANG, Joanna, COLONNO, Richard J, BALDICK, Carl J, LEVINE, Steven M, POKORNOWSKI, Kevin A, WALSH, Ann W, JIE FANG, YU, Cheng-Fang, SHARON ZHANG, MAZZUCCO, Charles E

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Inhibition of Hepatitis B Virus Polymerase by Entecavir by LANGLEY, David R, WALSH, Ann W, BALDICK, Carl J, EGGERS, Betsy J, ROSE, Ronald E, LEVINE, Steven M, JAYNE KAPUR, A, COLONNO, Richard J, TENNEY, Daniel J

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

A novel small molecule inhibitor of hepatitis C virus entry by Baldick, Carl J, Wichroski, Michael J, Pendri, Annapurna, Walsh, Ann W, Fang, Jie, Mazzucco, Charles E, Pokornowski, Kevin A, Rose, Ronald E, Eggers, Betsy J, Hsu, Mayla, Zhai, Weixu, Zhai, Guangzhi, Gerritz, Samuel W, Poss, Michael A, Meanwell, Nicholas A, Cockett, Mark I, Tenney, Daniel J

“…Small molecule inhibitors of hepatitis C virus (HCV) are being developed to complement or replace treatments with pegylated interferons and ribavirin, which…”
Get full text

Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir by Walsh, Ann W, Langley, David R, Colonno, Richard J, Tenney, Daniel J

“…Entecavir (ETV) is a deoxyguanosine analog competitive inhibitor of hepatitis B virus (HBV) polymerase that exhibits delayed chain termination of HBV DNA. A…”
Get full text

Antibodies to Modulate Surface Receptor Systems Are Often Bivalent and Must Compete in a Two‐Dimensional Cell Contact Region by Schmidt, Brian J., Bee, Christine, Han, Minhua, Jing, Yawu, Cheng, Yougan, Tenney, Daniel J., Leil, Tarek A.

“…Integrated experimental and modeling methods using both surface plasmon resonance–based kinetic measures and cell‐binding data have been used to account for…”
Get full text

Entecavir for Treatment of Hepatitis B Virus Displays No In Vitro Mitochondrial Toxicity or DNA Polymerase Gamma Inhibition by MAZZUCCO, Charles E, HAMATAKE, Robert K, COLONNO, Richard J, TENNEY, Daniel J

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response by Baldick, Carl J, Eggers, Betsy J, Fang, Jie, Levine, Steven M, Pokornowski, Kevin A, Rose, Ronald E, Yu, Cheng-Fang, Tenney, Daniel J, Colonno, Richard J

“…Background/Aims The efficacy of anti-viral therapy for chronic hepatitis B virus (HBV) is lost upon the emergence of resistant virus. Using >500 patient HBV…”
Get full text

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915) by Weber, Jeffrey S, Schadendorf, Dirk, Del Vecchio, Michele, Larkin, James, Atkinson, Victoria, Schenker, Michael, Pigozzo, Jacopo, Gogas, Helen, Dalle, Stéphane, Meyer, Nicolas, Ascierto, Paolo A, Sandhu, Shahneen, Eigentler, Thomas, Gutzmer, Ralf, Hassel, Jessica C, Robert, Caroline, Carlino, Matteo S, Di Giacomo, Anna Maria, Butler, Marcus O, Muñoz-Couselo, Eva, Brown, Michael P, Rutkowski, Piotr, Haydon, Andrew, Grob, Jean-Jacques, Schachter, Jacob, Queirolo, Paola, de la Cruz-Merino, Luis, van der Westhuizen, Andre, Menzies, Alexander M, Re, Sandra, Bas, Tuba, de Pril, Veerle, Braverman, Julia, Tenney, Daniel J, Tang, Hao, Long, Georgina V

“…Ipilimumab and nivolumab have each shown treatment benefit for high-risk resected melanoma. The phase III CheckMate 915 trial evaluated adjuvant nivolumab plus…”
Get full text

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B by Chang, Ting‐Tsung, Lai, Ching‐Lung, Kew Yoon, Seung, Lee, Samuel S., Coelho, Henrique Sergio M., Carrilho, Flair Jose, Poordad, Fred, Halota, Waldemar, Horsmans, Yves, Tsai, Naoky, Zhang, Hui, Tenney, Daniel J., Tamez, Ricardo, Iloeje, Uchenna

“…Sustained virologic suppression is a primary goal of therapy for chronic hepatitis B (CHB). In study entecavir (ETV)‐022, 48 weeks of entecavir 0.5 mg was…”
Get full text

High-throughput screening and rapid inhibitor triage using an infectious chimeric Hepatitis C virus by Wichroski, Michael J, Fang, Jie, Eggers, Betsy J, Rose, Ronald E, Mazzucco, Charles E, Pokornowski, Kevin A, Baldick, Carl J, Anthony, Monique N, Dowling, Craig J, Barber, Lauren E, Leet, John E, Beno, Brett R, Gerritz, Samuel W, Agler, Michele L, Cockett, Mark I, Tenney, Daniel J

“…The recent development of a Hepatitis C virus (HCV) infectious virus cell culture model system has facilitated the development of whole-virus screening assays…”
Get full text

Tyrosine-protein kinase SYK-related gene signature in baseline immune cells associated with adjuvant immunotherapy-induced immune-related adverse events in melanoma by Monson, Kelsey R, Ferguson, Robert, Handzlik, Joanna E, Xiong, Jiahan, Dagayev, Sasha, Morales, Leah, Chat, Vylyny, Bunis, Anabelle, Sreenivasaiah, Chaitra, Dolfi, Sonia, Tenney, Daniel J, Shao, Yongzhao, Osman, Iman, Weber, Jeffrey S, Kirchhoff, Tomas

“…Immune checkpoint inhibition (ICI) shows benefits in adjuvant (AT) and neoadjuvant (NAT) melanoma treatments. However, ICI frequently induces severe…”
Get full text

Frontline Science: OX40 agonistic antibody reverses immune suppression and improves survival in sepsis by Unsinger, Jacqueline, Walton, Andrew H., Blood, Teresa, Tenney, Daniel J., Quigley, Michael, Drewry, Anne M., Hotchkiss, Richard S.

“…A defining feature of protracted sepsis is development of immunosuppression that is thought to be a major driving force in the morbidity and mortality…”
Get full text

Ultrasensitive Genotypic Detection of Antiviral Resistance in Hepatitis B Virus Clinical Isolates by JIE FANG, WICHROSKI, Michael J, TENNEY, Daniel J, LEVINE, Steven M, BALDICK, Carl J, MAZZUCCO, Charles E, WALSH, Ann W, KIENZLE, Bernadette K, ROSE, Ronald E, POKORNOWSKI, Kevin A, COLONNO, Richard J

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

A multi‐omic single cell sequencing approach to develop a CD8 T cell specific gene signature for anti‐PD1 response in solid tumors by Kumar, Namit, Papillon‐Cavanagh, Simon, Tang, Hao, Wang, Shiliang, Stromko, Caitlyn, Ho, Ching‐Ping, Soni‐Sheth, Sonal, Vasquez‐Grinnell, Steven, Broz, Miranda L., Tenney, Daniel J., Wichroski, Michael J., Walsh, Alice M., Hu, Yanhua, Benci, Joseph L.

“…Immune checkpoint blockade (ICB) has led to durable clinical responses in multiple cancer types. However, biomarkers that identify which patients are most…”
Get full text

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B by Colonno, Richard J., Rose, Ronald, Baldick, Carl J., Levine, Steven, Pokornowski, Kevin, Yu, Cheng F., Walsh, Ann, Fang, Jie, Hsu, Mayla, Mazzucco, Charles, Eggers, Betsy, Zhang, Sharon, Plym, Mary, Klesczewski, Kenneth, Tenney, Daniel J.

“…Comprehensive monitoring of genotypic and phenotypic antiviral resistance was performed on 673 entecavir (ETV)‐treated nucleoside naïve hepatitis B virus (HBV)…”
Get full text

Development, Characterization, and Radiation Dosimetry Studies of 18F-BMS-986229, a 18F-Labeled PD-L1 Macrocyclic Peptide PET Tracer by Kim, Joonyoung, Donnelly, David J., Tran, Tritin, Pena, Adrienne, Shorts, Andrea Olga, Petrone, Thomas V., Zhang, Yunhui, Boy, Kenneth M., Scola, Paul M., Tenney, Daniel J., Poss, Michael A., Soars, Matthew G., Bonacorsi, Samuel J., Cole, Erin L., Grootendorst, Diederik J., Chow, Patrick L., Meanwell, Nicholas A., Du, Shuyan

“…Purpose In cancer immunotherapy, the blockade of the interaction between programmed death-1 and its ligand (PD-1:PD-L1) has proven to be one of the most…”
Get full text

Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance by Baldick, Carl J., Tenney, Daniel J., Mazzucco, Charles E., Eggers, Betsy J., Rose, Ronald E., Pokornowski, Kevin A., Yu, Cheng F., Colonno, Richard J.

“…Virologic resistance emerging during entecavir (ETV) therapy for hepatitis B virus (HBV) requires three substitutions in the viral reverse transcriptase (RT),…”
Get full text